ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has suspended registration of three drug products that do not qualify the criteria of safety, efficacy and quality (SEQ).
The suspended drug products include painkiller tablets of Diclofenac Potassium in strengths of 75 and 100 mg, liquid suspension of anti-ulcer drug Famotidine in strengths of 10mg/5ml and 40mg/5ml, and a combination drug product containing paracetamol, thioridazine and caffeine. In a press release issued here on Saturday, DRAP has advised healthcare professionals, patients and their attendants to desist from prescribing or using these drug products as there is very less data on their SEQ.
Ag APPISLAMABAD: Prime Minister Shehbaz Sharif led a government delegation on Thursday to meet Jamiat Ulema-e-Islam...
Ag AgenciesBEIJING: Pakistan and China have agreed to strengthen bilateral cooperation in multiple sectors, including...
RAWALPINDI: Former foreign minister Shah Mahmood Qureshi on Thursday advised people against pinning hopes on US...
ISLAMABAD: The Judicial Commission of Pakistan (JCP) Thursday recommended nine advocates of the Supreme Court for...
ISLAMABAD: An international climate change conference kicked off at the Jinnah Convention Centre here on Thursday,...
By Mumtaz AlviLAHORE: An anti-corruption court in Lahore on Thursday acquitted Prime Minister Shehbaz Sharif and his...
ISLAMABAD: The National Accountability Bureau (NAB) has taken notice of a recent report by The News highlighting the...
ISLAMABAD: The first formal meeting of the Public Accounts Committee (PAC) will convene on February 12 to begin the...